Kirsten Fischer Selected Research

obinutuzumab

6/2022	Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
4/2022	Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.
1/2022	Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
1/2022	Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.
1/2022	Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
12/2021	Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
1/2021	Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
12/2020	High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.
1/2020	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
6/2019	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kirsten Fischer Research Topics

Disease

52	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 06/2022 - 10/2009
10	Residual Neoplasm 02/2022 - 03/2017
10	Neoplasms (Cancer) 02/2022 - 05/2011
7	Disease Progression 01/2022 - 01/2015
7	Neutropenia 01/2022 - 03/2014
6	Infections 01/2022 - 03/2014
2	Atrial Fibrillation 01/2022 - 01/2017
1	B-Cell Lymphoma (Lymphoma, B Cell) 02/2022
1	Myocardial Infarction 01/2022
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Exanthema (Rash) 01/2022
1	Hemorrhage 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Leukemia 01/2022
1	Glioblastoma (Glioblastoma Multiforme) 01/2021
1	Multiple Myeloma 01/2021
1	Leukocytosis (Pleocytosis) 01/2021
1	Genomic Instability 01/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2021
1	Tumor Lysis Syndrome 12/2020
1	Lymphoid Leukemia 12/2020
1	Sepsis (Septicemia) 01/2020
1	Obesity 01/2020
1	Septic Shock (Toxic Shock Syndrome) 01/2020
1	Trisomy (Trisomies) 01/2020
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2020
1	COVID-19 01/2020
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2019
1	Leukoencephalopathies 10/2017
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 10/2017
1	Lymphoma (Lymphomas) 06/2016
1	Mucositis 06/2016
1	Carcinogenesis 10/2015
1	Renal Cell Carcinoma (Grawitz Tumor) 05/2011
1	Pathologic Complete Response 02/2011
1	Body Weight (Weight, Body) 10/2009

Drug/Important Bio-Agent (IBA)

19	Rituximab (Mabthera)FDA Link 02/2022 - 09/2011
16	obinutuzumabIBA 06/2022 - 03/2014
13	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2022 - 08/2013
13	fludarabineIBA 01/2022 - 10/2009
12	venetoclaxIBA 01/2022 - 11/2017
10	ibrutinibIBA 01/2022 - 01/2015
8	Bendamustine Hydrochloride FDA Link 01/2022 - 09/2011
5	Chlorambucil (Leukeran)FDA Link 01/2020 - 10/2009
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 05/2011
3	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 05/2015
3	Lenalidomide (CC 5013)FDA Link 01/2021 - 09/2016
2	tirabrutinibIBA 06/2022 - 04/2022
2	idelalisibIBA 06/2022 - 03/2018
2	Immunoglobulins (Immunoglobulin)IBA 11/2021 - 11/2020
2	ofatumumab FDA Link 01/2021 - 03/2018
2	Thymidine KinaseIBA 01/2020 - 01/2018
1	6- (1H- indazol- 6- yl)- N- (4- morpholinophenyl)imidazo(1,2- a)pyrazin- 8- amineIBA 04/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2022
1	Prednisone (Sone)FDA LinkGeneric 02/2022
1	Vincristine (Oncovin)FDA LinkGeneric 02/2022
1	Cytochrome P-450 CYP3AIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2022
1	AnticoagulantsIBA 01/2022
1	hydrogen sulfite (bisulfite)IBA 01/2021
1	acalabrutinibIBA 01/2021
1	Phosphotransferases (Kinase)IBA 12/2020
1	AntibodiesIBA 12/2020
1	pipoxolan (BR 18)IBA 02/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	Genetic Markers (Genetic Marker)IBA 10/2017
1	Alemtuzumab (Campath)FDA Link 03/2017
1	Dihydrotachysterol (AT 10)IBA 03/2017
1	Anti-Bacterial Agents (Antibiotics)IBA 06/2016
1	Cisplatin (Platino)FDA LinkGeneric 06/2016
1	Oxygen (Dioxygen)IBA 06/2016
1	purineIBA 06/2015
1	Tyrosine Kinase InhibitorsIBA 05/2015
1	HLA-DR Antigens (HLA-DR)IBA 05/2011

Therapy/Procedure

16	Therapeutics 02/2022 - 10/2009
5	Drug Therapy (Chemotherapy) 02/2022 - 02/2011
2	Aftercare (After-Treatment) 01/2018 - 01/2016
1	Hematopoietic Stem Cell Transplantation 01/2019
1	Duration of Therapy 03/2018